Literature DB >> 1106217

A placebo-controlled study of lithium combined with neuroleptics in chronic schizophrenic patients.

J G Small, J J Kellams, V Milstein, J Moore.   

Abstract

Lithium combined with major tranquilizers was administered to 22 hospitalized chronic schizophrenic patients with minimal neurotoxicity or other side effects. Moreover, 10 of the patients benefited significantly with lithium as compared to placebo in terms of blind psychiatric and nursing ratings and nonblind clinical judgments of outcome. These results contrast with previous negative reports in the literature and the generally poor prognosis in chronic schizophrenic patients. The authors suggest that a trial combining lithium with psychotropic drugs is warranted in schizophrenic patients who do not respond satisfactorily to conventional treatment

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1106217     DOI: 10.1176/ajp.132.12.1315

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  11 in total

1.  Efficacy of lithium in schizophrenia.

Authors:  S Dube; B B Sethi
Journal:  Indian J Psychiatry       Date:  1981-07       Impact factor: 1.759

2.  Lithium poisoning. Report of a case with neurologic, cardiac and hepatic sequelae.

Authors:  L H Warick
Journal:  West J Med       Date:  1979-03

Review 3.  Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders.

Authors:  Chi-Tso Chiu; De-Maw Chuang
Journal:  Pharmacol Ther       Date:  2010-08-10       Impact factor: 12.310

4.  Addition of lithium to haloperidol in non-affective, antipsychotic non-responsive schizophrenia: a double blind, placebo controlled, parallel design clinical trial.

Authors:  W H Wilson
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

5.  Pharmacokinetics of lithium: elimination half-time, renal clearance and apparent volume of distribution in schizophrenia.

Authors:  R W Mason; E G McQueen; P J Keary; N M James
Journal:  Clin Pharmacokinet       Date:  1978 May-Jun       Impact factor: 6.447

6.  Concept and Management of Treatment Resistant Schizophrenia (TRS).

Authors:  Nitesh Painuly; Nitin Gupta; Ajit Avasthi
Journal:  Indian J Psychiatry       Date:  2004-04       Impact factor: 1.759

Review 7.  Lithium. Current status in psychiatric disorders.

Authors:  M Peet; J P Pratt
Journal:  Drugs       Date:  1993-07       Impact factor: 9.546

Review 8.  The use of carbamazepine in the treatment of schizophrenic and schizoaffective psychoses: a review.

Authors:  C Simhandl; K Meszaros
Journal:  J Psychiatry Neurosci       Date:  1992-03       Impact factor: 6.186

9.  Treatment of the special patient with schizophrenia.

Authors:  R R Conley; D L Kelly
Journal:  Dialogues Clin Neurosci       Date:  2001-06       Impact factor: 5.986

Review 10.  Lithium for schizophrenia.

Authors:  Stefan Leucht; Bartosz Helfer; Markus Dold; Werner Kissling; John J McGrath
Journal:  Cochrane Database Syst Rev       Date:  2015-10-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.